Table 3.
Multivariate Analysis of Treatment-Related Mortality, Relapse, Progression-Free Survival, and Overall Survival
| Variables | Relative Risk (95% CI) | P-Value |
|---|---|---|
| Treatment related mortality | ||
| Main effect: | ||
| U Chicago | 1.00/Referent | .3 |
| MDACC | 1.44 (0.7–2.9) | |
| Other significant covariates: | ||
| Related and matched | 0.37 (0.18–0.76) | <.01 |
| Relapse | ||
| Main effect: | ||
| U Chicago | 1.00/Referent | |
| MDACC | 0.56 (0.3–1.05) | .07 |
| Other significant covariates: | ||
| Dose | 0.2 (0.05–0.75) | .01 |
| Risk group | 2.67 (1.7–4.1) | <.01 |
| Progression-free survival | ||
| Main effect: | ||
| U Chicago | 1.00/Referent | |
| MDACC | 0.8 (0.5–1.3) | .3 |
| Other significant covariates: | ||
| Risk Group | 2.06 (1.5–2.8) | <.01 |
| Related and matched | 0.6 (0.4–0.9) | .03 |
| Overall survival | ||
| Main effect: | ||
| U Chicago | 1.00/Referent | |
| MDACC | 0.9 (0.56–1.43) | .6 |
| Other significant covariates: | ||
| Risk group | 2.00 (1.45–2.75) | <.01 |
| Related and matched | 0.6 (0.4–0.9) | .02 |
| Acute GVHD Grade II–IV | ||
| Main effect: | ||
| UC | 1.00/Referent | |
| MDACC | 5.45 (2.8–10.3) | <.01 |
| Other significant covariates: | ||
| Related and matched | 0.5 (0.28–0.93) | .02 |
| Acute GVHD Grade III–IV | ||
| Main effect: | ||
| U Chicago | 1.00/Referent | |
| MDACC | 2.9 (0.87–9.5) | .08 |
| No significant covariates | ||
| Chronic GVHD | ||
| Main effect: | ||
| UC | 1.00/Referent | |
| MDACC | 6.6 (2.8–15.4) | <.01 |
| No significant covariates | ||
MDACC indicates M.D. Anderson Cancer Center; GVHD, graft-versus-host disease.